Other languages Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
0.8737 ^USD	+9.21%		+7.48%	-57.17%

04-29	Gritstone Bio, Inc. Announces Board Changes	CI
04-15	Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Gritstone Bio, Inc. Announces Board Changes	04-29
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform	04-15
Top Midday Decliners	04-02
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants	04-02
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall	04-01
Gritstone Bio Starts Public Offering; Shares Drop After-Hours	04-01
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite	04-01
Gritstone bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-05
Gritstone Bio Announces Update to Comparative Phase 2B Covid-19 Clinical Trial	02-12
Gritstone bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-08
Gritstone Bio, Inc. Announces Presentation of Results from Three Ongoing Phase 1 Studies Evaluating Its Self-Amplifying Mrna Vaccine Candidates Against Covid-19 (Part of the Company?s Coral Program) at IDWeek 2023	11/10/23
Gritstone bio Offers Stock Options to Three New Employees	10/10/23
Investors Await GDP, Jobless Claims as US Futures Trend Lower in Thursday's Premarket	28/09/23
Gritstone Bio Gets Contract For Comparative COVID-19 Trial; Shares Jump After-Hours	27/09/23
Gritstone Bio, Inc. Receives BARDA Contract to Conduct Comparative Phase 2b Study Evaluating Next-Generation Vaccine Candidate for COVID-19	27/09/23
Gritstone bio, Genevant Sciences Sign License Agreement for Use of LNP Technology	15/08/23
Gritstone Bio and Genevant Sciences Announce Option and License Agreement	15/08/23
Gritstone bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/08/23
Gritstone Joins Collaborative Cancer Research Initiative; Shares Rise 4% Pre-Bell	07/08/23
Moderna/Merck inicia estudio de fase final de combinación de vacunas contra el cáncer de piel	26/07/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Other languages

Filters